Empagliflozin as add-on to metformin in people with Type 2 diabetes.

@article{Merker2015EmpagliflozinAA,
  title={Empagliflozin as add-on to metformin in people with Type 2 diabetes.},
  author={Ludwig Merker and H G H{\"a}ring and Anita Vedel Christiansen and Flavien Roux and Afshin Salsali and Gabriel Kim and Thomas W Meinicke and H. J. Woerle and Uli C. Broedl},
  journal={Diabetic medicine : a journal of the British Diabetic Association},
  year={2015},
  volume={32 12},
  pages={1555-67}
}
AIMS To investigate the long-term efficacy and safety of empagliflozin as add-on to metformin in people with Type 2 diabetes. METHODS Of 637 participants treated with empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily for 24 weeks, 463 (72.7%) were treated in a double-blind extension trial for ≥ 52 weeks. Prespecified exploratory endpoints included changes from baseline in HbA1c , weight and blood pressure at week 76. RESULTS Compared with placebo, adjusted mean changes from… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Similar Papers

Loading similar papers…